Pfizer has announced progress in its research programme to develop antivirals and vaccine for the Covid-19 coronavirus infection.
The company identified a lead drug candidate. According to findings from initial screening assays, analogues of the compound are potent SARS-CoV-2 3C-like (3CL) protease inhibitors.
Pfizer said that preliminary data revealed antiviral activity of the candidate against the novel coronavirus. The company will conduct pre-clinical confirmatory studies, including anti-viral profiling and suitability for intravenous administration clinically.
Furthermore, the company is making preparations to conduct a clinical study of the lead candidate in the third quarter of this year. Azithromycin review The company is